Nutraceuticals

A guide for healthcare professionals

Second edition

Brian Lockwood

BPharm, PhD, MRPharmS

Senior Lecturer in Pharmacy,
School of Pharmacy and Pharmaceutical Sciences,
University of Manchester,
Manchester, UK

London • Chicago Pharmaceutical Press
Contents

Preface xiii
Acknowledgements xvi
About the author xvii
Abbreviations xviii

1 Introduction 1
Foods or medicines? The relationship between nutraceuticals, foods and medicines 1
The use of nutraceutical supplements – demographic trends 6
Safety 9
Scientific evidence 10
Market trends 12
Major nutraceuticals and their applications 15
Overview 15
References 15

2 Monographs – general and specific properties 19
Glucosamine 19
Chondroitin 20
Methylsulfonylmethane 21
Coenzyme Q10 22
Melatonin 23
Carnitine 24
Acetyl-l-carnitine 26
Octacosanol/policosanol 27
S-Adenosyl methionine 28
Polyunsaturated fatty acids 29
n-3 Fatty acids from fish oils 30
γ-Linolenic acid 31
Flaxseed/α-linolenic acid 32
Conjugated linoleic acid 33
Flax lignans 34
Pycnogenol 35
Resveratrol 37
Grape seed proanthocyanidin extract 38
Lycopene 39
Lutein 41
Zeaxanthin and astaxanthin 41
α-Lipoic acid 42
Dehydroepiandrosterone 43
Soy isoflavones 44
Tea 47
Creatine 52
References 53

3 Source, manufacture and analysis of major nutraceuticals 59
References 64

4 Metabolism, bioavailability and pharmacokinetics of nutraceuticals 69
Metabolism data 69
Bioavailability data 69
Pharmacokinetic data 75
References 79

5 Joint health 85
Prevalence of joint disease 85
Glucosamine and chondroitin 87
Methylsulfonylmethane 97
S-Adenosyl methionine 98
Fish oils 99
γ-Linolenic acid 102
Cetylated fatty acids 104
Miscellaneous nutraceuticals 105
Conclusions 106
References 106

6 Cardiovascular health 111
Black and green tea 113
Soy 119
n-3 and n-6 Essential fatty acids 124
Flax lignans 130
Coenzyme Q10 131
Lycopene 133
Octacosanol/policosanol 136
Pycnogenol 138
Melatonin 140
Contents ix

Resveratrol 140
Grape seed proanthocyanidin extract 141
Lutein 143
Carnitine 143
Dehydroepiandrosterone 145
Conclusions 145
References 146

7 Eye health 155
Age-related macular degeneration 155
Lutein and zeaxanthin 156
Other eye conditions 161
Conclusions 164
References 165

8 Mental health 169
Acetyl-L-carnitine 170
Phosphatidylserine 173
Docosahexaenoic acid 174
Soy isoflavones 175
Other nutraceuticals 175
Treatments for depression 177
Conclusions 178
References 178

9 Sleep enhancement 183
Melatonin 183
Miscellaneous 188
References 188

10 Cancer prevention 191
Epidemiological evidence for soy 192
Tea 200
Lycopene 206
Flaxseed 211
n-3 Polyunsaturated fatty acids 212
Coenzyme Q10 214
Melatonin 215
Conjugated linoleic acid 218
Overall conclusions 220
References 220
16 **Oral health**  
Tea 297  
Pycnogenol 299  
Coenzyme Q10 299  
References 299

17 **Enhancement of sporting performance**  
Creatine 301  
Carnitine 304  
Acetyl-L-carnitine 305  
Octacosanol 305  
Conjugated linoleic acid 306  
Other nutraceuticals 306  
Conclusion 308  
References 308

18 **Animal health**  
Cardiovascular disease 311  
Joint disease 316  
Periodontal disease 320  
Cognitive dysfunction 321  
Cancer 322  
Conclusions 323  
References 324

19 **Meta-analyses and systematic reviews of nutraceutical clinical trials**  
References 332

20 **Synergism, beneficial interactions and combination products**  
Glycoaminoglycan supplementation in arthritis, liver injury and pain 340  
Beneficial interactions between nutraceuticals and medicines 345  
Combination products 348  
Commercially available combinations 351  
Conclusions 352  
References 352

21 **Minor nutraceuticals and their therapeutic applications**  
Theanine 359  
Cetyl myristoleate 363
<table>
<thead>
<tr>
<th>Contents</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduced form of nicotinamide adenine dinucleotide</td>
<td>364</td>
</tr>
<tr>
<td>Superoxide dismutase</td>
<td>364</td>
</tr>
<tr>
<td>Polyamines</td>
<td>365</td>
</tr>
<tr>
<td>Other candidates</td>
<td>365</td>
</tr>
<tr>
<td>References</td>
<td>366</td>
</tr>
<tr>
<td>22 Safety, adverse effects and interactions of nutraceuticals</td>
<td>369</td>
</tr>
<tr>
<td>Safety data</td>
<td>369</td>
</tr>
<tr>
<td>General adverse effects</td>
<td>369</td>
</tr>
<tr>
<td>Drug interactions</td>
<td>372</td>
</tr>
<tr>
<td>Carnitine and acetylcarnitine</td>
<td>373</td>
</tr>
<tr>
<td>Soy isoflavones</td>
<td>374</td>
</tr>
<tr>
<td>Catechins</td>
<td>375</td>
</tr>
<tr>
<td>Melatonin</td>
<td>376</td>
</tr>
<tr>
<td>Glucosamine</td>
<td>377</td>
</tr>
<tr>
<td>Conclusions</td>
<td>378</td>
</tr>
<tr>
<td>References</td>
<td>379</td>
</tr>
<tr>
<td>23 Quality of nutraceuticals</td>
<td>383</td>
</tr>
<tr>
<td>Glucosamine and chondroitin products</td>
<td>384</td>
</tr>
<tr>
<td>Other nutraceuticals</td>
<td>386</td>
</tr>
<tr>
<td>Non-formulated products</td>
<td>388</td>
</tr>
<tr>
<td>Possible contaminants in nutraceuticals</td>
<td>390</td>
</tr>
<tr>
<td>Analytical issues</td>
<td>392</td>
</tr>
<tr>
<td>Other quality issues</td>
<td>393</td>
</tr>
<tr>
<td>Cost comparisons of different products</td>
<td>395</td>
</tr>
<tr>
<td>Conclusions</td>
<td>395</td>
</tr>
<tr>
<td>References</td>
<td>396</td>
</tr>
<tr>
<td>24 Conclusions</td>
<td>401</td>
</tr>
<tr>
<td>Future trends influencing consumers</td>
<td>401</td>
</tr>
<tr>
<td>Future trends facing manufacturers</td>
<td>404</td>
</tr>
<tr>
<td>Scientific community, regulatory authorities and consumer organisations</td>
<td>405</td>
</tr>
<tr>
<td>New horizons</td>
<td>407</td>
</tr>
<tr>
<td>Overall</td>
<td>407</td>
</tr>
<tr>
<td>References</td>
<td>408</td>
</tr>
<tr>
<td>Index</td>
<td>409</td>
</tr>
</tbody>
</table>